07 Jan 2001

Nucleo cmp - España

Updated: 07 Jan 2001

Nucleo cmp "forte" 30 capsulas

Neuralgias (lumbago, ciática, otalgias, etc), neuritis (herpes zoster, parálisis facial, polineuritis, recuperación de hemipléjicos, poliomielíticos, etc).

Nucleo cmp Description, Presentation and Dosage

Nucleo cmp Description

Nucleo cmp Drug Class Description

Complejo b, otras asociaciones

Nucleo cmp Drug Description

CAPSULAS

Nucleo cmp Presentation

Nucleo cmp Presentation

Vía im ("Forte"):. - Adultos: 1 inyectable cada 24 h. - Niños: medio inyectable cada 24 h o 1 inyectable cada 48-72 h. Vía oral ("Normal" y "forte"):. - Adultos: 1 cápsula 3 veces al día. - Niños: 1 cápsula 2 veces al día.

Nucleo cmp Manufacturer

FERRER INTERNACIONAL

Related Learning Zones

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

Cystic fibrosis (CF) is a genetic condition caused by a defect in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. The Cystic Fibrosis Knowledge Centre provides healthcare professionals with access to disease awareness information, emerging and established treatment options and current best practice based on recently updated guidelines by the European Cystic Fibrosis Society (ECFS). A resources section contains external links to upcoming medical conferences and patient support groups.

This resource is developed by EPG Health Media for epgonline.org, supported by an independent educational grant from Vertex.

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis is intended for healthcare professionals involved in the treatment and management of patients with psoriasis. This resource has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A. Users can expect to find sections containing expert videos, clinical slide decks, congress highlights, key publications and links to useful resources.

This resource has been developed in collaboration with Novartis Pharma AG.

Nucleo cmp Dosage

Nucleo cmp Precautions, Reactions and Contraindications

Nucleo cmp Special Precautions

Related Drugs - Gastroenterologia

Back to top